Evidence map›Paper›PMID 42545738›Full record

ReviewJournal of the American Society of Nephrology : JASN2026

Hypertension Management in Pregnancy and Postpartum.

Line Malha, Phyllis August

Abstract readReview
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Line MalhaDivision of Nephrology and Hypertension, Department of Medicine, Weill Cornell Medicine, New York, New York; and Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-1980-7798

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertensive disorders of pregnancy affect approximately 9% of pregnancies in the United States and are a leading cause of maternal morbidity and mortality. For nephrologists, these conditions sit at a critical intersection: CKD is among the strongest risk factors of preeclampsia, and pregnancy itself can unmask previously unrecognized kidney disease. The physiologic demands of gestation stress renal and vascular reserve in ways that make the pregnant and immediately postpartum patient particularly vulnerable. Preeclampsia, driven by placental release of antiangiogenic factors and widespread maternal endothelial dysfunction, produces acute cardiorenal injury that does not entirely resolve with delivery. Postpartum hypertension peaks between days 3 and 6 after delivery and is under-recognized, yet this period carries the greatest risk of preventable maternal death, with cardiovascular causes accounting for more than one third of pregnancy-related deaths. Beyond the acute phase, women with hypertensive pregnancies face accelerated trajectories toward chronic hypertension, CKD, and overall cardiometabolic risks that compound with each affected pregnancy. The postpartum visit represents a critical and underutilized opportunity to identify women who warrant nephrology evaluation, initiate renoprotective therapy, and interrupt a long-term cardiorenal disease course. Nephrologists are well positioned to recognize cardiorenal sequelae of hypertensive pregnancy and ensure that the postpartum period is not a missed opportunity for intervention. This review addresses the diagnosis, pathophysiology, and management of hypertensive disorders across the full peripartum continuum, with particular attention to the role of nephrologists in recognizing kidney disease that pregnancy has brought to light and in ensuring that delivery is not treated as a clinical end point.

Indexed as

HypertensionHypertension, Pregnancy-InducedPuerperal DisordersAntihypertensive AgentsFemaleHumansPostpartum PeriodPre-EclampsiaPregnancyPregnancy Complications, CardiovascularRenal Insufficiency, ChronicAntihypertensive AgentsBPkidney diseasewomen's health

Identifiers

PMID42545738
PMCPMC13641443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.